A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (Core OLE)
Completed · Phase 2 · NCT04712669
Conditions: Pulmonary Arterial Hypertension
At a glance
- Research payments reported, 2025
- $24,698
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 108
About the trial
- Sponsor
- Altavant Sciences GmbH
- Tested
- rodatristat ethyl 300 mg tablet BID (drug), rodatristat ethyl 600 mg BID (drug), Placebo (drug)
- Dates
- Started 2021-03-15; completion 2023-08-28
- Results posted
- Yes
The purpose of this study is to assess the safety and efficacy of Rodatristat Ethyl in pulmonary arterial hypertension (PAH) patients.
From ClinicalTrials.gov, last updated 2025-06-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sumitomo Pharma America, Inc. reported $24,698 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.